In this study, we want to learn more about the impact on progression-free survival (PFS) for patients with multiple myeloma when taking a combination of four drugs. The four drugs in this study are lenalidomide, ixazomib, dexamethasone, and daratumumab.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
Transplant
20-0064
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
